newsfilter
← Latest News
GlobeNewswire·

Beneficient Closes $8.75 Million GP Primary Capital Transaction

  • Beneficient (NASDAQ: BENF) closed an $8.75 million primary capital commitment in Quartus AI Fund LP, a fund managed by New York-based Quartus Capital Partners LLC.
  • In exchange for an interest in the Fund, Beneficient received $8.75 million in stated value of its Resettable Convertible Preferred Stock, which is convertible into Class A common stock at the holder's election.
  • The transaction follows Beneficient's GP Primary Commitment Program, which provides primary capital solutions to qualifying private investment funds.
  • Following the closing, Beneficient holds an unrealized gain of approximately $1.2 million derived from the pro rata appreciation of the Fund's existing asset portfolio.
  • The collateral for Beneficient's ExAlt loan portfolio is expected to increase by approximately $9.77 million, with a corresponding addition of $9.77 million in tangible book value for stockholders.
  • Quartus AI Fund LP invests in growth-stage vertical AI ventures across high-value sectors, currently holding nine portfolio investments, eight of which are US-based.
  • Quartus Capital Partners LLC was awarded Best Performing US Emerging Manager for 2024 by Private Equity Wire, & the Fund has performed in the top quartile of Cambridge Associates Benchmark Indices over the past two-plus years.
  • The Fund's investor base includes endowments, foundations, RIAs, & single- & multifamily offices.
  • Beneficient Interim CEO James Silk stated the partnership reflects the company's commitment to driving shareholder value & enhancing collateral backing its loan portfolio.
  • A reconciliation of non-GAAP financial measures indicates tangible book value attributable to public company stockholders will increase to $9.77 million pro forma.
  • The transaction requires stockholder approval for the issuance of Class A common stock upon conversion of the Preferred Stock, & Beneficient will file preliminary & definitive proxy statements with the SEC.
  • The press release includes standard forward-looking statement disclaimers regarding risks & uncertainties that could cause actual results to differ from projections.